S-Methyl-L-cysteine structure
|
Common Name | S-Methyl-L-cysteine | ||
---|---|---|---|---|
CAS Number | 1187-84-4 | Molecular Weight | 135.185 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 242.8±30.0 °C at 760 mmHg | |
Molecular Formula | C4H9NO2S | Melting Point | ~240 °C (dec.) | |
MSDS | Chinese USA | Flash Point | 100.7±24.6 °C |
Use of S-Methyl-L-cysteineS-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities. |
Name | S-methyl-L-cysteine |
---|---|
Synonym | More Synonyms |
Description | S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities. |
---|---|
Related Catalog | |
In Vivo | S-Methyl-L-cysteine (100 mg/kg) results in significant attenuation of plasma glucose, insulin, tumor necrosis factor-alpha, insulin resistance and improved antioxidant enzyme activities[1]. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 242.8±30.0 °C at 760 mmHg |
Melting Point | ~240 °C (dec.) |
Molecular Formula | C4H9NO2S |
Molecular Weight | 135.185 |
Flash Point | 100.7±24.6 °C |
Exact Mass | 135.035400 |
PSA | 88.62000 |
LogP | 0.47 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.509 |
Storage condition | -20°C |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xn: Harmful; |
Risk Phrases | R22 |
Safety Phrases | S22-S24/25-S36/37/39-S26 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
Precursor 10 | |
---|---|
DownStream 10 | |
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer.
PLoS ONE 10 , e0127063, (2015) Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncology indications, including ulcerative colitis and colorectal cancer. MMP9 is a downstream effector and... |
|
Cysteine amide adduct formation from carboxylic acid drugs via UGT-mediated bioactivation in human liver microsomes.
Pharmazie 70 , 678-83, (2015) Although chemical trapping has been widely used to evaluate cytochrome P450-mediated drug bioactivation, thus far, only a few in vitro-trapping studies have been performed on UDP-glucuronosyltransfera... |
|
Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.
Bioorg. Med. Chem. Lett. 17 , 3921-4, (2007) Inhibition of Eg5 represents a novel approach for the treatment of cancer. Here, we report the synthesis and structure-activity relationship of S-trityl-L-cysteine (STLC) derivatives as Eg5 inhibitors... |
L-methylcysteine |
(2R)-2-(Methylamino)-3-sulfanylpropanoic acid |
S-METHYL-CYSTEINE |
H-Cys(Me)-OH |
SMC |
Methylcysteine |
DL-S-Methyl-cysteine |
N-Methyl-L-cystein |
Cysteine, N-methyl, L- |
(R)-N-Methylcysteine |
S-Methyl-L-cysteine |
(2R)-2-amino-3-methylsulfanyl-propionic acid |
EINECS 214-701-6 |
L-Cysteine, N-methyl- |
L-Cysteine,S-methyl |
N-Méthyl-L-cystéine |
L-CH3SCH2CH(NH2)COOH |
N-Methyl-L-cysteine |
H-L-CYS(ME)-OH |
MFCD00002612 |
(R)-2-Amino-3-(methylmercapto)propionic acid SMLC |
S-Methyl-L-Cys-OH |